Atenolol @ ( *** ) - Beta- Adrenergic blocker- (FDC- List )- (2006)Drug Name:
Atenolol @ ( *** ) - Beta- Adrenergic blocker- (FDC- List )- (2006)
List Of Brands:
Indication Type Description:
Dosages/ Overdosage Etc
Interaction with Food
Pregnancy and lactation
Beta-adrenergic blockers include-
Atenolol, Acebutol, Betaxolol, Bisoprolol,Cartelol,Esmolol, Labetatol,Metoprolol, Nadolol,Penbutolol, Pinodol, Propranolol, Solatol, Timolol,
Refer - Atenolol
Interacting drugs -summary
Aluminium salts /Barbiturates/Calcium salts / Choestyramine/Cloestipol/ NSAIDs/
Penicillin- Ampicillin/ Rifamipin/Salicylates/ Sulfinpyrazone
bioavailability and plasma levels of certain beta blockers may be decreased by these agents, possibly resulting in a decreased pharmacologic effect.
pharmacologic effects of beta-blockers as well as nifedipine and verapramil may be potentiated,. Diltiazem , felodipine and nicardipine
may increase the effect of the beta-blockers. Monitor cardiac function
and decrease the beta-blocker dose if necessary.
bioavailability and plasma levels of certain betablockers may be increased
Ethanol + Propranolol
Additive CNS inhibition , increased propranolol levels and increased clearance
Flecianide + Betablockers+ Flecainide
bioavailability of either agent may be increased, possibly increasing the pharmacologic effects
Haloperidol + Betablocker/Betablockers + Haloperidol
pharmacologic effects (hypotensive episodes ) of both drugs may be
H2 antagonists + Metoprolol/Propranolol
pharmacolkinetic parameters of betablocker metabolized by cytochrome
P-450 may be altered by cimetidine, pharmacodynamic effects may be
increased .Ranitidine may increase the bioavailability of metoptolol.
Hydralazine + Metoprolol/propranolol / Betaprolol + hydrazine
serum levels and pharmacolgic efects of betablockers and hydrazine may
Loop diuretics + Propranolol
propranolol plasma levels and cardiovascular effects may be enhanced.
Atenolol was not affected
MAO inhibitors + Metoprolol/Nadolol
bradycardia may develop during concurrent use
Phenothiazine + Propranol/ Betablockers + Phenothiazine
propranolol bioavailability and plasma levels and phenothiazine plasma
levels may be increased, possibly resulting in increased effects
Propafenone + Betablockers- Metoprolol/propranol
plasma levels of beta blockers metabolized by the liver may be increased
plasma betablocker levels may be increased possibly resulting in increased effects
Quinolones + Ciproflocxacin
bioavailability of betablockers metabolised by cytochrome P-450 may be increased
Thioamines + betablockers- Metoprolol/ Propranol
pharmacokinetics of betablockers may be altered, increased pharmacologic effects
acetoaminophen clearance may be increased
Propranol may increase the anticoagulant effect of warfarin
effects of benzodiapines may be increased by lipophylic beta blockers.
Atenolol does not interact
life-threatening and fatal increases in blood pressure have occured after
discontinuation of clonoidine in patients receiving a beta blocker or
disopyramide clearance may be decreased, adverse effects may occur (sinus
hypertensive episode followed by bradycardia may occur
peripheral ischemia manifested by cold extremities, possible peripheral gangrene
Nondepolraizing muscle relaxants
betablockers may potentiate,counteract or have no effect on the actions of the nonpolarizing muscle relaxants
concurrent administration may increase the postural hypotension produced by prazosin
hypoglycemic effects of sulfonylureas may be attentuated
reduced elimination of theophylline may occur. of one or both agents.
Angina pectoris, hypertension, acute myocardial infarction.
Beta -Adrenergic blockers
Most adverse reactions are mild and transcient and rarely require withdrawal of therapy
Hypersensitivity- Pharnyngitis, photosentivity reacion , erythematous rash, fever combined with aching and sore throat.larhngospam, respiaratory distress,angioedema, anaphylaxis
Cardiovascular- bradycardia, torsades de pointes and other serious new ventricullar arrhythmias, cardiovascular disorder, AICD discharge,
shortness of breath, peripheral vascular insufficiency (cold extremities, paresthesia of hands),arterial insufficiency usually of Raynauds type claudication, heart failure, CHF, sinoartrial block,cerbral vascular accident,
Hyperglycemia, hypoglycemia, unstable diabetes.
Gastric/epigastric pain, flatulence, gastritis, constipation, nausea, diarrhea, colon problem, dry mouth. vomiting, heartburn, appetite disorder, anorexia, bloating, abdominal discomfort/and renal and mesentric arterial thrombosis, ischemic colitis,
Sexual dysfunction, impotence or decreased libido, dysuria, nocturia, pollakuria, urinary retention or frequency, urinary tract infection, cystitis, renal colic, GU dosorder, renal failure.
Agranulocytrosis, nonthrombocytopenic or thrombocytopenic purpura, bleeding,
thrombocytopenia, eosinophilia, leukopenia, pulmonary emboli, hyperlipdemia.
Rash, pruritus, skin irritation, increased pigmentation, sweating/hyperhodrosis,
alopecia (includingreversible) dry skin, psoriasis (often reversible), acne, eczema, flushing, exfoliative dermatitis, peripheral skin necrosis, psoriasiform rash, or exacerbation of psoriasis, purpura, erythermatous rash.
Eye irritation/ discomfort, visual disturbances, dry/burning eyes, blurred vision,
conjunctivitis, ocular pain/pressure, abnormal lacremation.
Bronchospasm, dyspnea, cough, bromncial obstruction, rales, wheezing, nasal stiffness, pharyngitis, laryngospasm with respiratory distress, asthma, rhinitis, sinusitis, pulmonary problem,upper respiratory tract infection.
Joint pain, arthalgia, muscle cramps/pain, back.neckpain, arthritis, twitching/tremor,
localized pain, extremirty pain, myalgia.
Facial swelling, weight gain, weight loss, decreased excercise tolerance, lupus
syndrome, Raynauds phenomenon, speech disorder, rogoors, earache, gout, asthenia, malaise, fever, death.
Lab test abnormalities-
Propranol may elevate urea levels in patients with severe heart disease.
Propranol and metoprolol may cause elevated serum transaminase , alkaline phostase and LDH.
Tomol may produce slight increaes in BUN, serum potassium and serum uric acid and slight increases in hemoglobin hematocrit and HDL chloesterol, increase in liver function tests have been reported.
Minor persistenet elevations in AST and ALT have occured in patients treated with Pinodol.
Beta -Adrenergic Blockers
Sinus,bradycardia,heart-block greater than 2nd degree untreated cardiac failure, cardiogenic shock.
Variant angina,acute MI, bronchospamic diseases,diabetic melitus,peripheral vascular disorders, hepatic & renal dysfunction,elderly patients.
Diabetes/hypoglycemia- beta blockers may blunt premonitory signs and symptoms (eg tachycardia,blood pressure changes) of acute hypoglycemia. Atenolol does not potentiate insulin-induced hypoglycemia and unlike nonselective blockers,does not delay recovery of blood glucose to normal levels.
Beta blockers may mask clinical signs (eg tachycardia) of developing or continuing
hyperthyroidism.Abrupt withdrawal may exacerbate symptoms of hyperthyroidism.
Serum lipid concntrations-
Beta blcokers may alter serum lipids including an increase in the
concentration of total triglycerides, total cholesterol and LDL and VLDL cholesterol and a decrease of HDL cholesterol.
Muscle weakness- beta blockade has potentiated muscle weakness consistent with certain myasthenic symptoms ( eg. diplopia, ptosis, generalized weakness). Timolol rarely increased weakness in some patients with myasthenic symptoms.
Drug /Lab interactions-
These agents may produce hypoglycemia and interfere with glucose
or insulin tolerance tests.
Propranol may interfere with the glaucoma screening due to a reduction intraocular pressure.
Mortality- an exceesive mortality was seen in patients traeted with encainamide of flecanide, and a similar excess had been seen with moricizine.
Proarrhythmias- like other antiarrhythmic agents, solatol can provoke new or worsened
ventricular arrhythmias,in some patients including sustained ventricular fibrillation, with potentially fatal consequences.
Cardiac faliure- sympathetic stimulation is a vital component supporting circulatory function in CHF, and beta blockade carries the potential hazard of further depressing myocardial contracttility and precipating more severe failure.
Administer cautiously in hypertensive patients who have CHF controlled by digitalis and diuretics.
Wolff-Parkinson -White syndrome- in several carse tachycardia wss replaced by a severe bradycardia requiring a demand pacemaker after Popranolol administeration with as little as 5mg.
Abrupt withdrawal- occurence of beta-blocker withdrawal syndrome is contraversial. however, hypersenitivity to catecholamines has been observed in patients withdrawn from beta-blocker therapy.
Peripheral vascular disease- treatment with beta antagonists reduces cardiac output and precipitate or aggrevate the symptoms of arterial insiufficiency in patients with peripheral or mesentric vascular disease..
Excercise caution with such patients and observe closely for evidence of progression of aterial obstruction.
Nonallergic bronchospasm- (eg chronic bronchitis, emphysema)- in general do not administer beta blockers to patients with bronchospastic diseases. Administer Nadolol, Timolol, Penbutrol, Propranol, Solatol, Pinodol with caution, since they may block bronchodilation produced by endogenous or exogenous catecholamine stimulation of B2 receptors.
Bradycardia- Metoprolol produces a decrease in sinus heart rate in most patients, this decrease is greatest among patients with high initial rates and least among patients with low initial heart rates.
Phochromocytoma- It is hazardous to use propranol unless alpha adrenergic blocking agents are in use. since this would predispose to serious blood pressure elevation.
Sinus bradycardia- Heart rate (< 50bpm) occured in 13% of patients receiving solatol in clinical trials. and lead to discontinuation in in about 3%.
Electrolyte disturbances- do not use Sotalol in patients with hypokalemia or hypomagnesmia prior to correction of imbalace, as these conditions can exaggerrate the degree of QT prologation and decrease the potential for torsades de pointes.
Hypotension- if hypotension (systolic blood pressure < 90 mm Hg ) occurs, discontinue drug and carefully assess patients hemodynamic status and extent of myocardial damage.
Anaphylaxis- has occured and may include symptoms such as profound hypotensiuon , bradycardia with or without AV nodal block, severe sustained bronchospasm.and angioedema. Deaths have occured.
Anesthesia and major surgery- necessity or desirability of withdrawing betablockers prior to major surgery is contraversial. Beta blockade impairs the hearts ability to respond to beta adrenergically mediated reflux stimuli.
AV block- Metoprolol slows AV conduction and may produce significant first (PR interval, second , or third degree heart block. Acute MI also produces heart block. If heart block occurs, discontinue metoprolol.
Sick sinus syndrome- use sotalol only with extreme caution in patients with sick sinus syndrome associated with symptomatic arrhythmias, because it may cause sinus bradycardia, sinus pauses or sinus arrest.
Renal /hepatic function impairment- use with caution.
Pregnancy- Safety for use during pregnancy has not been established. Use only when clearly needed.
Lactation- Although adverse effects in the infants have not been demonstrated in general, nursing should not be undertaken by mother s receiving these drugs
Children- safety and efficacy for use in children have not been established
Dosages/ Overdosage Etc:
Angina pectoris, hypertension, acute myocardial infarction.
Initial dose- 50mg daily. Increase upto 100mg daily if required. Dosage more than 100mg
unlikely to produce any additional benefit.
Symptoms Patients underlying disease state may contribute significantly. The main features are bradycardia and hypotension
Cardiovascular- bradycardia, hypotension, CHF, cardiogenic shock,intravenrticular conduction, AV Block (all degrees) asytole, pulmonary edema tachycardia and hypertension (pinodol) ststemic vascular resistence ( propranalol)
CNS- depressed consciousness, coma, seizures, respiratory depression
Other- bronchospasm, especially in persons with obstructive pulmonary disease, hypoglycemia, hyperkalemia.
1. Place patients in supine ositionand raise legs if necessary to improve blood supply to the brain.
2. Measure blood glucose and serum potassium levels
3. Conitinously monitor blood pressure and ECG.
4. Chest X-Rays may demonstrate pulmonary edema.
5. Employ respiratory support, emesis (using syrup of Ipecac) or lavage and administer charcoal if necessary.
6. Treatment includes usual supportive measures
7. Administer IV glucose to treat hypoglycemia
8.Seizures respond to IV diazepam or if necessary phenytoin.
9. Nadolol and atenolol can be removed by hemodialysis
10. Propranol, labetolol, metoprolol , bisoprolol and timol are not significantly dialyzable.
11. In determining the duration of corrective therapy, consider their long duration of effect
12. Bradycardia- if hemodynamically stable no specific therapy s indicated.
If hypotensive, give 0.6mg IV or epinephrine
13. Ventricular premature contractions- are best treated with lidocaine or if necessary phenytoin.
14. Cardiac failure- administer a digitalis glycoside and oxygen
15. Hypotension- place patient in trendelburg position, treat bradyarrhytmias.
Administer IV fluids unless pulmonary edema is present
16. Heart block(secondary or third degree ) use isoproterenol or transvenous cardiac pacemaker.
17. Bronchospasm- administer a beta 2 stimulating agent, epinephrine or theophylline derivative.
1. Do not miss any doses.This is specially important when yountaking one dose per day. Some conditions may become worse oif not taken regularly.
2. If you do miss a dose take it as soon as possible.
3. However, if it is within 4 hours of your next dose ( 8 hours when using atenolol, betaxolol.bisoprolol,
Cartteolol, labetalol, nadolol, pnbutolol,solatol, or extended release (longacting) metoprolol, oxprenonol, or propranolol) skip the missed dose and go back to your dosing schedule
4. Do not double doses.
1. Do not discontinue medication abruptly, except on advise of physician. Sudden cessation of therapy may precipitate or exacerabate angina.
2. Consult pharmacist or physician before using other products which may contain alpha adrenergic stimulants (eg. nasal decongestants, otc cold preparations)
3. Notify physician if symptoms of CHF occur (eg. difficult breathing, especially on exertion or when lying down., night cough, swelling of the extremities).
4. Notify physician if any of these occur; slow pulse rate, dizziness, lightheadedness, confusion or depression, skin rsh, fever, sore throat or unusual bleeding or bruising.
5. May produce drowsiness, lightheaedness, blurred vision, patient should observe caution while driving or performing tasks requiring alertness, coordination or physical dexterity.
6. Allergies- Tell your doctor if you had any unusual or allergic reactions to bet-blockers.
Tell your doctor if you are allergic to any other substances such as foods, or drink
7. Pregnancy- use of beta-blockers during pregnancy has been associated with low blood sugar, breathing problems, a slower heart rate, low blood pressure in the new born infant.
8. Breast-feeding- it is not known whether bisoprolol, carteolol or pentbutol pass into breast milk. Mothers who are taking beta blockers and who wish to breast feed should discuss with the doctor.
9. Children- some of these medicines have been used in children and in effective doses, have not shown to cause side effects.
10. Elderly- Side effects are more likely to occur in elderly. Beta blockers may reduce tolerance to cold temperature in elderly patients
11. Other medicines- Tell your doctor if you are taking any other medicines-
Allergy shots or Allergy skin tests - betablockers may increase the risk of serious allergic reactions
12. Other medical problems- Tell your doctor if you have other medical problems-
Allergy or Bronchitis or Emphysema - betablockers may increase trouble in breathing of this medicine may be increased because of slow removal from the body
13. Missed dose-
If you miss of this medicine take it as soon as possible.
However, it it is within 4 hours of your next dose ( 8 hrs if you are using atenolol, labetolol, madolol, penbutol, solatolol or extended release metoprolol,oxeprenol, or propranol,) skip the next dose and go back to your dosing schedule
Do not double doses.
Interaction with Food:
Food enhances the bioavialabilty of Metoprolol andPropranol . This effect is not noted with Nadolol, Bisoprolol or Pinodol. Sotalol absorption is reduced approximately by a standard meal.
Pregnancy and lactation:
Safety for use during pregnancy has not been established. Use with caution in pregnant woman.
Known to be excreted in breast milk. Nursing should not be undertaken by mothers receiving these drugs.
Safety and efficacy for use in children have not been established.